Hospital-acquired pneumonia medical therapy: Difference between revisions
Jump to navigation
Jump to search
(/* Supportive trial data {{cite journal |author=Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J |title=Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized...) |
(/* Supportive trial data {{cite journal |author=Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J |title=Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized...) |
||
| Line 20: | Line 20: | ||
* Renal toxicity were more common in [[vancomycin]] compared to [[linezolid]] | * Renal toxicity were more common in [[vancomycin]] compared to [[linezolid]] | ||
===Supportive trial data <ref name="pmid22247123">{{cite journal |author=Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J |title=Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study |journal=[[Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America]] |volume=54 |issue=5 |pages=621–9 |year=2012 |month=March |pmid=22247123 |doi=10.1093/cid/cir895 |url=http://www.cid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=22247123 |accessdate=2012-09-11}}</ref>=== | ===Supportive trial data <ref name="pmid22247123">{{cite journal |author=Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J |title=Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study |journal=[[Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America]] |volume=54 |issue=5 |pages=621–9 |year=2012 |month=March |pmid=22247123 |doi=10.1093/cid/cir895 |url=http://www.cid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=22247123 |accessdate=2012-09-11}}</ref>=== | ||
In a study done in 1184 patients treated with [[linezolid]] and [[vancomycin]] no significant difference in 60 days mortality were found between the two groups. The side-effects profile were similar in both the groups however [[nephrotoxicity]] was commoner in the vancomycin group. | In a study done in 1184 patients treated with [[linezolid]] and [[vancomycin]] no significant difference in 60 days mortality were found between the two groups. The side-effects profile were similar in both the groups however [[nephrotoxicity]] was commoner in the vancomycin group. Linezolid was found to be non-inferior to vancomycin for clinical outcome, and microbiologic outcome at end of treatment and end of study. | ||
==References== | ==References== | ||
Revision as of 17:58, 11 September 2012
|
Hospital-acquired pneumonia Microchapters |
|
Differentiating Hospital-Acquired Pneumonia from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hospital-acquired pneumonia medical therapy On the Web |
|
American Roentgen Ray Society Images of Hospital-acquired pneumonia medical therapy |
|
Directions to Hospitals Treating Hospital-acquired pneumonia |
|
Risk calculators and risk factors for Hospital-acquired pneumonia medical therapy |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Philip Marcus, M.D., M.P.H.[2]
Overview
Antimicrobial therapy
Patients prone to Methicillin-resistant staphylococcus aureus
- Critically ill patients
- History of recent antibiotic therapy
- Patient admitted in a hospital with increased incidence of MRSA.
Antibiotic choice for MRSA
- Vancomycin
- Linezolid
- Teicoplanin
- In case no MRSA is isolated on culture these antibiotics should be discontinued.
Side-effects of Linezolid
- Thrombocytopenia
- Gastrointestinal side-effects
- Renal dysfunction
Side-effects of vancomycin
- Renal toxicity were more common in vancomycin compared to linezolid
Supportive trial data [1]
In a study done in 1184 patients treated with linezolid and vancomycin no significant difference in 60 days mortality were found between the two groups. The side-effects profile were similar in both the groups however nephrotoxicity was commoner in the vancomycin group. Linezolid was found to be non-inferior to vancomycin for clinical outcome, and microbiologic outcome at end of treatment and end of study.
References
- ↑ Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012). "Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 54 (5): 621–9. doi:10.1093/cid/cir895. PMID 22247123. Retrieved 2012-09-11. Unknown parameter
|month=ignored (help)